FDA Approves First Therapy for Newly Diagnosed PTCLs

PTCLs pic
Image: medscape.org

Trained at New York Medical College and the now-dissolved University of Medicine and Dentistry of New Jersey, Dr. Matthew Taub is a board-certified oncologist based in Florida. Drawing on decades of experience, Dr. Matthew Taub provides evidence-based medical treatment in accordance with guidelines published by the National Cancer Committee Network for a wide range of cancers.

Until recently, no FDA-approved treatment existed for patients with newly-diagnosed CD30-expressing peripheral T-cell lymphomas (PTCLs). Now, the FDA recommends treating PTCLs using brentuximab vedotin injection in conjunction with chemotherapy. This conclusion was made within two weeks of submission to the agency due to the new Real-Time Oncology Review (RTOR) program. Intended to expedite the clinical availability of lifesaving treatments, the RTOR was just launched this past July.

The FDA looked at the ECHELON-2 clinical trial involving 452 patients with PTCLs when it made its decision. Patients in the trial received standard chemotherapy or chemotherapy with brentuximab vedotin injection. In the later arm of the study, patients experienced a median of 48 months of progression-free survival compared to 21 months for the control group with a P-value of 0.01.


Lactoferrin May Help Alleviate Side Effects of Chemotherapy

Lactoferrin pic
Image: webmd.com

Possessing more than two decades of professional experience, Dr. Matthew Taub is a board-certified oncologist who also trained in hematology. Dr. Matthew Taub treats patients through Everglades Oncology and Hematology in Miramar, Florida. Relying on evidence-based practices in oncology, he continually seeks out new information that can improve the patient experience, especially in relation to chemotherapy.

Researchers have recently found that a daily lactoferrin supplement may help mitigate some of the taste and smell abnormalities observed in patients who undergo chemotherapy. About 60 to 70 percent of patients experience these issues in relation to this treatment, but researchers have still not identified the underlying cause. Alleviating these symptoms could help generate more optimism among patients battling cancer.

The initial study, conducted at Virginia Polytechnic Institute (Virginia Tech), involved only 19 patients and 12 healthy controls. The researchers associated taste and smell abnormalities with high levels of salivary iron and the loss of certain salivary immune proteins. Lactoferrin supplementation was found to reduce salivary iron significantly while increasing immune proteins like annexin A1 and proteinase inhibitor. In addition, there was a significant reduction in the taste and smell abnormality score among patients undergoing chemotherapy, with a P-value of less than 0.001.

Immunotherapy Vital to New Hematologic Cancer Approaches

Immunotherapy pic
Image: webmd.com

Dr. Matthew Taub treats patients with cancer as an oncologist at Everglades Oncology and Hematology in Florida. Emphasizing evidence-based care, Dr. Matthew Taub also has extensive experience as a practicing hematologist focused on blood-related diseases.

As reported in the Oncology Times, one promising area of treatment involves the use of immunotherapy to address hematologic malignancies. One type of immunotherapy, allogeneic hematopoietic stem cell transplantation (HCT), has been employed for decades and has proved invaluable in treating leukemia in patients who undergo stem cell transplantation.

Immunological responses are a critical factor when undertaking HCT stem cell grafts, as the body often mounts immune responses against the transplants. Individualizing the immunotherapy approach with the help of big data enables the graft-versus-leukemia effect without triggering graft-versus-host disease.

Another advancement in immunotherapy involves CAR T-cell therapy, which has been FDA approved since 2017 and is effective in treating acute lymphoblastic leukemia. The new approach involves reprogramming healthy cells in ways that direct them to destroy cancer cells.

The Role of Clinical Oncologists in Cancer Treatment


NCCN Global Initiatives Making Cancer Research Accessible


National Comprehensive Cancer Network pic
National Comprehensive Cancer Network
Image: nccn.org

Board-certified oncologist Dr. Matthew Taub possesses more than two decades of experience administering care to patients with benign and malignant tumors. In his work as an oncology physician, Dr. Matthew Taub follows the industry-respected guidelines put forward by the National Comprehensive Cancer Network (NCCN) to evaluate treatment options for his patients.

To extend the impact of its research and initiatives, NCCN collaborates with cancer organizations around the world. In Africa, NCCN partners with the African Cancer Coalition to improve cancer patient outcomes in sub-Saharan Africa by expanding access to basic care. NCCN also has a strong presence in Asia and Europe, with more than 800,000 NCCN registered practitioners working on these continents.

To facilitate knowledge and resource sharing across its diverse membership base, NCCN translates its guidelines and content into several languages, including French, Korean, and Spanish. NCCN also adapts its guidelines to reflect regional differences in healthcare infrastructure, technology access, and genetic differences in populations.

How Benign Tumors Differ from Malignant Tumors


Image: webmd.com

Dr. Matthew Taub, a physician with Optimum Oncology Hematology Associates, has been practicing medicine for more than 20 years. Throughout that time, Dr. Matthew Taub has treated both benign and malignant tumors.

Benign tumors are noncancerous growths that do not spread to other areas of the body. Although no specific cause of benign tumors is known, they have been linked to chronic inflammation, traumatic injury, and diet. Regardless, benign growths are common and can develop in any part of the body.

Though they are not cancerous, benign tumors can cause health problems, depending on their size and location. The growths may press against primary nerves or main arteries or compress brain matter. In these cases, the tumors will need to be treated or removed. Fortunately, benign tumors respond well to treatment and rarely grow back.

Infrequently, benign tumors can develop into malignant tumors. Because of this, benign tumors are typically monitored very closely, especially if they are classified as premalignant, which means the tumors have a high likelihood of becoming cancerous in the future.

Create your website at WordPress.com
Get started